Search bioRxivSearch

Biology subjects

Numanagic, I.

Publications and source records attributed to Numanagic, I..

2 recordsLinked to original sources

Latent variable model for aligning barcoded short-reads improves downstream analyses

Recent years have seen the emergence of several \"third-generation\" sequencing platforms, each of which aims to address shortcomings of standard next-generation short-read sequencing by producing data that capture long-range information, thereby allowing us to access regions of the genome that are inaccessible with short-reads alone. These technologies either produce physically longer reads typically with higher error rates or instead capture long-range information at low error rates by virtue of read \"barcodes\" as in 10x Genomics Chromium platform. As with virtually all sequencing data, sequence alignment for third-generation sequencing data is the foundation on which all downstream analyses are based. Here we introduce a latent variable model for improving barcoded read alignment, thereby enabling improved downstream genotyping and phasing. We demonstrate the feasibility of this approach through developing EMerAld-- or EMA for short-- and testing it on the barcoded short-reads produced by 10xs sequencing technologies. EMA not only produces more accurate alignments, but unlike other methods also assigns interpretable probabilities to the alignments it generates. We show that genotypes called from EMAs alignments contain over 30% fewer false positives than those called from Lariats (the current 10x alignment tool), with a fewer number of false negatives, on datasets of NA12878 and NA24385 as compared to NIST GIAB gold standard variant calls. Moreover, we demonstrate that EMA is able to effectively resolve alignments in regions containing nearby homologous elements-- a particularly challenging problem in read mapping-- through the introduction of a novel statistical binning optimization framework, which allows us to find variants in the pharmacogenomically important CYP2D region that go undetected when using Lariat or BWA. Lastly, we show that EMAs alignments improve phasing performance compared to Lariats in both NA12878 and NA24385, producing fewer switch/mismatch errors and larger phase blocks on average.\n\nEMA software and datasets used are available at http://ema.csail.mit.edu.

bioinformatics

Computational proteogenomic identification and functional interpretation of translated fusions and micro structural variations in cancer

MotivationRapid advancement in high throughput genome and transcriptome sequencing (HTS) and mass spectrometry (MS) technologies has enabled the acquisition of the genomic, transcriptomic and proteomic data from the same tissue sample. In this paper we introduce a novel computational framework which can integratively analyze all three types of omics data to obtain a complete molecular profile of a tissue sample, in normal and disease conditions. Our framework includes MiStrVar, an algorithmic method we developed to identify micro structural variants (microSVs) on genomic HTS data. Coupled with deFuse, a popular gene fusion detection method we developed earlier, MiStrVar can provide an accurate profile of structurally aberrant transcripts in cancer samples. Given the breakpoints obtained by MiStrVar and deFuse, our framework can then identify all relevant peptides that span the breakpoint junctions and match them with unique proteomic signatures in the respective proteomics data sets. Our framework's ability to observe structural aberrations at three levels of omics data provides means of validating their presence.\n\nResultsWe have applied our framework to all The Cancer Genome Atlas (TCGA) breast cancer Whole Genome Sequencing (WGS) and/or RNA-Seq data sets, spanning all four major subtypes, for which proteomics data from Clinical Proteomic Tumor Analysis Consortium (CPTAC) have been released. A recent study on this dataset focusing on SNVs has reported many that lead to novel peptides [1]. Complementing and significantly broadening this study, we detected 244 novel peptides from 432 candidate genomic or transcriptomic sequence aberrations. Many of the fusions and microSVs we discovered have not been reported in the literature. Interestingly, the vast majority of these translated aberrations (in particular, fusions) were private, demonstrating the extensive inter-genomic heterogeneity present in breast cancer. Many of these aberrations also have matching out-of-frame downstream peptides, potentially indicating novel protein sequence and structure. Moreover, the most significantly enriched genes involved in translated fusions are cancer-related. Furthermore a number of the somatic, translated microSVs are observed in tumor suppressor genes.\n\nContactcenksahi@indiana.edu

bioinformatics